CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Ceribell (CBLL) reported insider activity by its Chief Technology Officer, Raymond Woo. On 11/11/2025, he exercised options for 1,472 shares at $2.24, and 3,025 and 6,615 shares at $4.70, then sold 11,112 shares under a Rule 10b5-1 trading plan. The sale’s weighted-average price was $12.28, with trades ranging from $12.00 to $12.52. Following these transactions, his directly held common stock was 167,704 shares. Related options remain outstanding with expirations through 2033 as disclosed.
CeriBell (CBLL) reported Q3 2025 results with total revenue of $22.589 million, up from $17.195 million a year ago, driven by product revenue of $17.020 million and subscription revenue of $5.569 million. Gross profit was $19.942 million.
Operating expenses rose to $34.589 million, leading to a net loss of $13.465 million (basic and diluted loss per share $0.37). For the nine months, revenue reached $64.279 million with a net loss of $39.885 million.
Liquidity remained strong with $168.5 million in cash, cash equivalents, and marketable securities as of September 30, 2025 ($23.739 million cash and $144.803 million marketable securities). Year‑to‑date operating cash outflow was $30.034 million. Notes payable carried value was $19.745 million. The company cites adoption in 600+ active accounts and use in 200,000+ patients as of the quarter end.
Ceribell, Inc. (CBLL) furnished an update on its latest performance, announcing that it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company stated that the information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under the Exchange Act, nor incorporated by reference under the Securities Act unless specifically referenced.
CeriBell, Inc. filed a universal shelf registration to offer up to $300,000,000 of securities — including common stock, preferred stock, debt securities, warrants, and units — to be sold from time to time in one or more offerings. A prospectus supplement will set the specific amounts, prices, and terms for each takedown and may update the base disclosures.
The company may sell through underwriters, dealers, agents, directly to purchasers, or a combination of these methods. Use of proceeds will be described in the applicable supplement. CeriBell’s common stock trades on the Nasdaq Global Select Market under “CBLL”; the last reported price was $11.34 per share on November 3, 2025.
Ceribell, Inc. (CBLL) insider activity on 10/03/2025 shows the Chief Technology Officer, Raymond Woo, executed option exercises and open-market sales under a Rule 10b5-1 plan.
Mr. Woo exercised 1,472 options at a $2.24 strike, 3,025 options at $4.7, and 6,615 options at $4.7, increasing his reported beneficially owned common shares to 178,816 before a sale. He sold 11,112 shares in multiple trades at a weighted average price of $12.54 (individual sale prices ranged $12.00–$12.99), and the sale was effected pursuant to a Rule 10b5-1 trading plan. The filing notes option vesting schedules and that one option is fully vested and exercisable.
Ceribell, Inc. (CBLL) notice reports proposed and completed insider sales of common stock. An insider planned to sell 11,112 shares through Fidelity Brokerage Services LLC with an aggregate market value of $139,314.51, and the filing lists 36,663,968 shares outstanding. The securities to be sold were acquired via stock options granted on 07/07/2021 (1,472 shares) and 02/16/2023 (9,640 shares), with payment noted as cash. The form also discloses a completed sale by Raymond Woo of 11,112 shares on 09/04/2025 for gross proceeds of $134,609.74. The filer certifies no undisclosed material adverse information and includes standard Rule 144 and Rule 10b5-1 notices.
Ceribell, Inc. reports updates to its long-term supply relationship with Shenzhen Everwin Precision Technology. The existing Corporate Supply Agreement, originally signed in January 2022, covers supply of Ceribell’s small and large headbands and licenses product materials needed to manufacture and support these products.
Amendment No. 1 extended the initial two-year term to January 9, 2025, and Amendment No. 2 further extended the term to December 31, 2027 while designating Everwin Precision Holding (Hong Kong) Company Limited as agent and providing for deliveries from a facility in Tijuana, Mexico. On September 22, 2025, Amendment No. 3 added Everwin Precision (Viet Nam) Technology as an additional agent of Everwin China to enable deliveries of headbands from a facility in Vietnam.
Ceribell, Inc. reported that, effective September 17, 2025, its Board of Directors elected Erica Rogers to serve as a director until the next annual meeting of stockholders and until a successor is duly elected and qualified, or her earlier resignation or removal.
She has also been appointed to the Board’s Compensation Committee. As a non-employee director, Ms. Rogers will receive annual cash compensation and restricted stock units under Ceribell’s Non-Employee Director Compensation Program, and the company will enter into its standard-form indemnification agreement with her. The company states there is no arrangement or understanding with any other person regarding her election and that she is not involved in related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Ceribell director Erica J. Rogers filed an initial Form 3 reporting her relationship to Ceribell, Inc. (CBLL) with an event date of 09/17/2025. The filing states that no securities are beneficially owned by the reporting person. The form was signed by an attorney-in-fact, Louisa Daniels, on 09/19/2025, and includes Exhibit 24 (Power of Attorney).
Ceribell, Inc. (CBLL) director Erica J. Rogers was granted 25,216 restricted stock units (RSUs) on 09/17/2025. The RSUs are reported at a $0 transaction price, and following the grant she is shown as beneficially owning 25,216 shares on a direct basis. The Form 4 was signed on behalf of Ms. Rogers by attorney-in-fact Louisa Daniels on 09/19/2025. The filing identifies Ms. Rogers as a director and indicates this is a single-person Form 4 filing for the issuer Ceribell, Inc., ticker CBLL. No derivative securities or other transactions are reported in this filing.